Turion Labs, a pioneering biotech venture formed by S&S LAB Korea and Future Lestari (Indonesia), has officially launched in Singapore during Ecosperity Week, unveiling a transformative vision to position Southeast Asia as a global innovation engine for medical and life sciences.
Designed as the region’s first full-stack biotech innovation platform, Turion Labs integrates shared laboratory infrastructure, contract research services (CRO), and regulatory enablement into a unified solution that supports biomedtech ventures from discovery to commercialisation.
Turion Labs’ first major facility is set to open later this year at the Sinarmas Land Biomedical Hub in BSD City, Indonesia — a newly designated Biomedical Special Economic Zone. This flagship site will host modular labs, pilot-scale research suites, and clinical support services, creating a powerful springboard for biotech development and commercialisation.
As part of its long-term strategy, Turion Labs is expanding its presence beyond Singapore and Indonesia, with upcoming projects planned in Thailand, Malaysia, and the Philippines. These efforts will form a distributed, cross-border biotech corridor designed to attract venture capital, connect research hubs, and reduce barriers to growth for life science startups and scaleups alike.
“We’re bridging the gap between high-potential science and scalable solutions,” said Dominic Jeong, CEO of S&S LAB Korea. “With Southeast Asia as our launchpad, we are building a connected platform that empowers global biotech innovators to gain access to Korean R&D excellence, Southeast Asian market pathways, and world-class lab infrastructure.”
